IP Library Assignment 073058/0504
Patent Assignment
Reel/Frame 073058/0504

Patent Security Agreement

Recorded: 2025-10-10 Pages: 17
Assignor
KARYOPHARM THERAPEUTICS INC.
Executed: 2025-10-10
Assignee
WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL TRUSTEE
500 DELAWARE AVENUE, 11TH FLOOR, WILMINGTON, DELAWARE, 19801
Covered Properties (65)
Hydrazide Containing Nuclear Transport Modulators and Uses Thereof
Application: 19/075,233 →
Publication: US US20260062391A1
Nuclear Transport Modulators and Uses Thereof
Application: 18/586,019 →
Publication: US US20250059158A1
Substituted Benzofuranyl and Benzoxazolyl Compounds and Uses Thereof
Application: 19/197,345 →
Publication: US US20260085064A1
Polymorphs of Selinexor
Application: 19/258,063 →
Publication: US US20260152489A1
Process for Preparing XPO1 Inhibitors and Intermediates for Use in the Preparation of XPO1 Inhibitors
Application: 17/607,670 →
Publication: US US20220242832A1
Crystalline Form of Selinexor
Application: 18/032,949 →
Publication: US US20230391754A1
Biomarkers for Selinexor
Application: 17/598,101 →
Publication: US US20220178927A1
Methods of Synthesis of Heteroaryl Derivatives of Triazolyl Acrylamides and Crystalline Forms
Application: 18/561,374 →
Publication: US US20240287041A1
Selinexor and Analogs for Use in the Treament of Endometrial Cancer in Patients with Wild-Type TP53 Gene
Application: 19/154,281 →
Uses of Il-12 as a Replacement Immunotherapeutic
Application: 16/318,670 →
Publication: US US20240181010A1
Il-12 Compositions and Methods of Use in Hematopoietic Recovery
Application: 17/368,346 →
Publication: US US20220168393A1
Co-Crystal Forms of Selinexor
Application: 17/446,664 →
Publication: US US20210395232A1
Nuclear Transport Modulators and Uses Thereof
Application: 18/526,900 →
Publication: US US20240376114A1
Nuclear Transport Modulators and Uses Thereof
Patent: 9,428,490 →
Application: 14/235,342 →
Publication: US US20150018332A1
Hydrazide Containing Nuclear Transport Modulators and Uses Thereof
Patent: 9,079,865 →
Application: 14/235,306 →
Publication: US US20140364408A1
Hydrazide Containing Nuclear Transport Modulators and Uses Thereof
Patent: 8,999,996 →
Application: 14/219,638 →
Publication: US US20140235653A1
Hydrazide Containing Nuclear Transport Modulators And Uses Thereof
Patent: 9,206,158 →
Application: 14/735,853 →
Publication: US US20150274698A1
Hydrazide Containing Nuclear Transport Modulators and Uses Thereof
Patent: 9,714,226 →
Application: 14/940,310 →
Publication: US US20160304472A1
Hydrazide Containing Nuclear Transport Modulators and Uses Thereof
Application: 15/629,307 →
Publication: US US20180127384A1
Hydrazide Containing Nuclear Transport Modulators and Uses Thereof
Application: 16/203,181 →
Publication: US US20190330164A1
Hydrazide Containing Nuclear Transport Modulators and Uses Thereof
Application: 16/696,702 →
Publication: US US20200339521A1
Hydrazide Containing Nuclear Transport Modulators and Uses Thereof
Application: 17/321,029 →
Publication: US US20220073478A1
Hydrazide Containing Nuclear Transport Modulators and Uses Thereof
Application: 18/244,659 →
Publication: US US20240279188A1
Nuclear Transport Modulators and Uses Thereof
Patent: 8,513,230 →
Application: 13/041,377 →
Publication: US US20110275607A1
Nuclear Transport Modulators and Uses Thereof
Patent: 9,550,757 →
Application: 13/931,372 →
Publication: US US20140155370A1
Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof
Patent: 9,938,258 →
Application: 14/647,662 →
Publication: US US20160221994A1
Methods of Promoting Wound Healing Using CRM1 Inhibitors
Application: 14/777,302 →
Publication: US US20160304500A1
Nuclear Transport Modulators and Uses Thereof
Patent: 9,738,624 →
Application: 14/900,469 →
Publication: US US20160152596A1
Nuclear Transport Modulators and Uses Thereof
Application: 15/651,856 →
Publication: US US20180155317A1
Nuclear Transport Modulators and Uses Thereof
Application: 16/519,955 →
Publication: US US20200199099A1
Nuclear Transport Modulators and Uses Thereof
Application: 17/409,150 →
Publication: US US20220177445A1
Substituted Benzofuranyl and Benzoxazolyl Compounds and Uses Thereof
Patent: 9,856,241 →
Application: 14/902,202 →
Publication: US US20160368904A1
Substituted Benzofuranyl and Benzoxazolyl Compounds and Uses Thereof
Application: 15/831,111 →
Publication: US US20180319779A1
Substituted Benzofuranyl and Benzoxazolyl Compounds and Uses Thereof
Application: 16/507,927 →
Publication: US US20200102292A1
Substituted Benzofuranyl and Benzoxazolyl Compounds and Uses Thereof
Application: 17/205,797 →
Publication: US US20210403459A1
Multicyclic Compounds And Methods Of Using Same
Patent: 9,994,558 →
Application: 15/023,269 →
Publication: US US20170096417A1
Polymorphs of Selinexor
Application: 15/503,319 →
Publication: US US20180215733A1
Polymorphs of Selinexor
Application: 16/679,630 →
Publication: US US20200283419A1
Polymorphs of Selinexor
Application: 17/365,656 →
Publication: US US20220135545A1
Polymorphs of Selinexor
Application: 18/131,273 →
Publication: US US20230242516A1
Polymorphs of Selinexor
Application: 18/132,241 →
Publication: US US20230242517A1
Polymorphs of Selinexor
Application: 18/226,570 →
Publication: US US20240208943A1
(S,E)-3-(6-Aminopyridin-3-Yl)-N-((5-(4-(3-Fluoro-3-Methylpyrrolidine-1-Carbonyl)Phenyl)-7-(4-Fluorophenyl)Benzofuran-2-Yl)Methyl)Acrylamide for the Treatment of Cancer
Application: 15/753,897 →
Publication: US US20180235948A1
Nuclear Transport Modulators and Uses Thereof
Application: 16/066,554 →
Publication: US US20190016690A1
Nuclear Transport Modulators and Uses Thereof
Application: 16/066,572 →
Publication: US US20190160063A1
Multicyclic Compounds and Uses Thereof
Application: 16/066,558 →
Publication: US US20190016710A1
The Combination of XPO1 Inhibitors and Second Agents for the Treatment of Prostate Cancer
Application: 17/273,884 →
Publication: US US20210315897A1
Nuclear Transport Modulators And Uses Thereof
Patent: 9,096,543 →
Application: 13/891,044 →
Publication: US US20130317031A1
Nuclear Transport Modulators and Uses Thereof
Patent: 9,266,843 →
Application: 14/399,868 →
Publication: US US20150111893A1
Nuclear Transport Modulators and Uses Thereof
Patent: 9,861,614 →
Application: 14/747,394 →
Publication: US US20160145246A1
Nuclear Transport Modulators and Uses Thereof
Patent: 9,585,874 →
Application: 14/989,377 →
Publication: US US20160354347A1
Nuclear Transport Modulators and Uses Thereof
Application: 15/413,889 →
Publication: US US20170319551A1
Nuclear Transport Modulators and Uses Thereof
Application: 15/831,048 →
Publication: US US20180289675A1
Nuclear Transport Modulators and Uses Thereof
Application: 16/037,798 →
Publication: US US20190008833A1
Nuclear Transport Modulators and Uses Thereof
Application: 16/414,479 →
Publication: US US20200038373A1
Nuclear Transport Modulators and Uses Thereof
Application: 16/840,841 →
Publication: US US20200230110A1
Nuclear Transport Modulators and Uses Thereof
Application: 17/179,512 →
Publication: US US20210251968A1
CRM1 Inhibitors for Treating Epilepsy
Application: 16/463,693 →
Publication: US US20190374527A1
A Method of Increasing Survival of a Human Subject Having Exposure to an Acute Exposure to Non-Therapeutic Whole Body Ionization by Administering a Therapeutically Effective Dose of Il-12
Patent: 8,921,315 →
Application: 12/430,016 →
Method for Treating Brain Cancer Using a Novel Tumor Suppressor Gene and Secreted Factor
Patent: 8,735,342 →
Application: 13/575,289 →
Publication: US US20130012452A1
Il-12 Formulations for Enhancing Hematopoiesis
Patent: 9,878,012 →
Application: 13/697,940 →
Publication: US US20130129674A1
Uses of Il-12 and the Il-12 Receptor Positive Cell in Tissue Repair and Regeneration
Patent: 8,962,317 →
Application: 13/824,224 →
Publication: US US20130259828A1
Mitigation of Cutaneous Injury with Il-12
Patent: 9,925,246 →
Application: 14/125,887 →
Publication: US US20140205561A1
Methods for Radiation Protection by Administering Il-12
Patent: 9,636,381 →
Application: 13/745,698 →
Publication: US US20130243722A1
Il-12 for Radiation Protection and Radiation-Induced Toxicity Mitigation
Patent: 9,616,106 →
Application: 14/372,738 →
Publication: US US20140369958A1
Related Assignments (17)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Sep 13, 2018
From: SANDANAYAKA, VINCENT P.; SHACHAM, SHARON; MCCAULEY, DILARA; SHECHTER, SHARON
To: KARYOPHARM THERAPEUTICS INC.
Reel/Frame 046870/0383 →
Notice of Security Interest in Patents Sep 27, 2019
From: KARYOPHARM THERAPEUTICS INC.
To: HCR COLLATERAL MANAGEMENT, LLC
Reel/Frame 050575/0574 →
Assignment of Assignor's Interest Jan 14, 2021
From: BASILE, LENA
To: NEUMEDICINES INC.
Reel/Frame 054926/0774 →
Assignment of Assignor's Interest Jan 13, 2022
From: BASILE, LENA A.
To: NEUMEDICINES, INC.
Reel/Frame 058639/0226 →
Assignment of Assignor's Interest Jan 14, 2022
From: NEUMEDICINES, INC.
To: KARYOPHARM THERAPEUTICS INC.
Reel/Frame 058661/0931 →
Assignment of Assignor's Interest Jun 13, 2022
From: NEUMEDICINES INC.
To: KARYOPHARM THERAPEUTICS INC.
Reel/Frame 060181/0342 →
Assignment of Assignor's Interest Nov 7, 2022
From: JOHNSON MATTHEY PUBLIC LIMITED COMPANY
To: MACFARLAN SMITH LIMITED
Reel/Frame 061888/0166 →
Assignment of Assignor's Interest May 19, 2023
From: HAMILTON, CLIFTON
To: JOHNSON MATTHEY PUBLIC LIMITED
Reel/Frame 063703/0155 →
Security Interest May 8, 2024
From: KARYOPHARM THERAPEUTICS INC.
To: WILMINGTON SAVINGS FUND SOCIETY, FSB
Reel/Frame 067345/0255 →
Second Lien Patent Security Agreement May 13, 2024
From: KARYOPHARM THERAPEUTICS INC.
To: WILMINGTON SAVINGS FUND SOCIETY, FSB
Reel/Frame 067396/0532 →
Assignment of Assignor's Interest Sep 13, 2024
From: MACFARLAN SMITH LTD. D/B/A VERANOVA
To: KARYOPHARM THERAPEUTICS INC.
Reel/Frame 068577/0890 →
Assignment of Assignor's Interest Mar 18, 2025
From: AUSTAD, BRIAN C.; ROE, DAVID G.
To: KARYOPHARM THERAPEUTICS INC.
Reel/Frame 070540/0244 →
Assignment of Assignor's Interest Oct 8, 2025
From: BALOGLU, ERKAN; SHACHAM, SHARON; MCCAULEY, DILARA; KASHYAP, TRINAYAN
To: KARYOPHARM THERAPEUTICS INC.
Reel/Frame 073030/0444 →
Patent Security Agreement Oct 10, 2025
From: KARYOPHARM THERAPEUTICS INC.
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT
Reel/Frame 073058/0647 →
Release of Security Interest in Patents at Reel/Frame No. 67396/0532 Oct 14, 2025
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS AGENT
To: KARYOPHARM THERAPEUTICS INC.
Reel/Frame 073111/0142 →
Assignment of Assignor's Interest Oct 23, 2025
From: AUSTAD, BRIAN C.; ROE, DAVID G.
To: KARYOPHARM THERAPEUTICS INC.
Reel/Frame 072650/0449 →
Assignment of Assignor's Interest Mar 31, 2026
From: BALOGLU, ERKAN; AUSTAD, BRIAN C.; ROE, DAVID G.; LEDUC, ANDREW
To: KARYOPHARM THERAPEUTICS INC.
Reel/Frame 075355/0889 →